1,749,142 Shares in UroGen Pharma Ltd. (NASDAQ:URGN) Bought by Toronto Dominion Bank

Toronto Dominion Bank acquired a new position in UroGen Pharma Ltd. (NASDAQ:URGN) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 1,749,142 shares of the company’s stock, valued at approximately $18,628,000. Toronto Dominion Bank owned 7.46% of UroGen Pharma at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the stock. KLP Kapitalforvaltning AS bought a new position in UroGen Pharma during the fourth quarter worth $59,000. Lazard Asset Management LLC acquired a new stake in UroGen Pharma during the 4th quarter worth about $67,000. Aquatic Capital Management LLC bought a new position in shares of UroGen Pharma in the 4th quarter worth about $101,000. Oppenheimer & Co. Inc. bought a new position in shares of UroGen Pharma in the 4th quarter worth about $126,000. Finally, ProShare Advisors LLC acquired a new position in shares of UroGen Pharma in the 4th quarter valued at about $137,000. 91.29% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. LADENBURG THALM/SH SH started coverage on UroGen Pharma in a report on Wednesday, February 19th. They issued a “buy” rating and a $31.00 target price for the company. Scotiabank started coverage on shares of UroGen Pharma in a research note on Wednesday, April 16th. They issued a “sector outperform” rating and a $23.00 price objective for the company. Guggenheim reissued a “buy” rating on shares of UroGen Pharma in a research note on Tuesday, April 29th. HC Wainwright reaffirmed a “buy” rating and issued a $55.00 price target on shares of UroGen Pharma in a research note on Tuesday, May 13th. Finally, D. Boral Capital reiterated a “buy” rating and set a $25.00 price objective on shares of UroGen Pharma in a report on Thursday, May 8th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $32.86.

UroGen Pharma Trading Up 9.0%

NASDAQ:URGN opened at $7.97 on Tuesday. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77. UroGen Pharma Ltd. has a one year low of $6.46 and a one year high of $20.70. The company has a market cap of $367.47 million, a PE ratio of -2.53 and a beta of 0.66. The firm has a 50-day moving average of $10.53 and a 200-day moving average of $10.85.

UroGen Pharma (NASDAQ:URGN) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.92) EPS for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.09). The business had revenue of $20.25 million during the quarter, compared to analysts’ expectations of $22.71 million. As a group, equities research analysts expect that UroGen Pharma Ltd. will post -3.12 EPS for the current fiscal year.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.